---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-019659"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:31:21.988116+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arcus Q1 net loss $80M, cash $1.0B; multiple Ph3 domvanalimab trials enrolling

## Summary
- Revenue $25M (up from $18M YoY); net loss $80M vs $68M in Q1 2022.
- Cash, equivalents and securities $1.0B; expected to fund operations into 2026.
- Four Phase 3 and two Phase 2 trials enrolling for domvanalimab combinations in lung and GI cancers.
- AB521 (HIF-2α inhibitor) dose-escalation enrolling 100mg; Phase 2 combo study in ccRCC expected Q3 2023.
- Three new drug candidates advancing to clinic: AB598 (anti-CD39) Q2 2023, AB801 (Axl inhibitor) H2 2023, AB375 (KIT inhibitor) early 2024.

## SEC filing metadata
- accession: 0000950170-23-019659
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000095017023019659/0000950170-23-019659-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000095017023019659/rcus-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-019659
- JSON: https://secwatch.observer/filing/0000950170-23-019659.json
- Plain text: https://secwatch.observer/filing/0000950170-23-019659.txt

## Key facts
- Earnings Releases
  Arcus Biosciences, Inc. reported the first quarter ended March 31, 2023 results: revenue $25 million.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $25 million
  - Result: reported results
  source text: cash in research and development activities. Cash, cash equivalents and marketable securities on-hand are expected to be sufficient to fund operations into 2026. • Revenues were $25 million for first quarter 2023, compared to $18 million for the same period in 2022. In first quarter 2023, Arcus recognized $17 million in license and development service revenues for
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000095017023019659/0000950170-23-019659-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.